Anew Labs, a drug‑discovery AI spin‑off from ByteDance, secured $290 million in its first external round, valuing the company at about $1.5 billion.
Anew Labs, the artificial‑intelligence drug‑discovery venture spun out of ByteDance, announced a $290 million Series A financing that pushes its valuation to roughly $1.5 billion.
Funding round details
The round was led by Sequoia Capital China, with participation from Hillhouse Capital, Tencent Investment, and several strategic investors from the biotech sector. Existing backers, including ByteDance’s own venture arm, also contributed to the round.
Anew Labs plans to allocate the capital toward expanding its proprietary AI platform, scaling pre‑clinical programs, and hiring additional scientific and engineering talent across its Shanghai and Boston offices.
Technology behind the spin‑off
The company leverages ByteDance’s large‑scale language‑model infrastructure to predict molecular interactions, accelerate hit identification, and optimize lead compounds. By integrating generative AI with high‑throughput screening data, Anew Labs claims it can cut early‑stage drug discovery timelines by up to 50 %.
Its platform, named “MoleculeGPT,” has already generated several candidate molecules that are entering pre‑clinical validation for oncology and neuro‑degenerative indications.
Market implications
The sizable raise underscores growing investor confidence in AI‑driven biotech, a sector that has seen a surge of interest after recent breakthroughs in protein‑folding prediction and generative chemistry.
Analysts note that Anew Labs’ valuation places it among the most valuable AI‑biotech startups globally, signaling that large tech firms are increasingly willing to spin off specialized units to attract dedicated capital.
- Accelerate AI model training with proprietary datasets
- Expand pre‑clinical pipelines in oncology, CNS, and rare diseases
- Scale global R&D footprint with new labs in Europe and Asia
We believe AI can fundamentally reshape how medicines are discovered, and this funding will help us bring that vision to patients faster.
The financing also positions Anew Labs to explore strategic partnerships with pharmaceutical companies seeking to augment their own discovery pipelines with AI capabilities.